Literature DB >> 33514406

Infection control strategy and primary care assistance in Campania region during the national lockdown due to COVID-19 outbreak: the experience of two tertiary emergency centers.

Angela Mauro1,2, Nicola Improda3,4, Letizia Zenzeri3, Francesco Valitutti5,6, Erica Vecchione3, Sara Esposito4, Vincenzo Tipo3.   

Abstract

BACKGROUND: COVID-19 pandemic has markedly affected emergency care, due to sudden limitation of health care capacity by general practitioners (GP) and urgent need for infection control strategies. We evaluated the activity of the Emergency Department (ED) during the national lockdown (March 8-April 30), as well as the outcomes of our infection control strategy.
RESULTS: Despite a reduction in access by one fifth, a proportion of febrile patients comparable to 2019 was seen (829/2492, 33.3% vs 4580/13.342, 34.3%, p = 0.3). Diagnostic swab for COVID-19 was performed in 25% of patients, especially in subjects with co-morbidities or multiple access. Six infected cases were identified, all presenting with febrile disease. Only two positive patients fulfilled the criteria for diagnostic swab provided by the Italian Health Authorities, because of close contact with suspected or confirmed cases. The rate of admission for febrile or respiratory conditions was higher than the same period of 2019 (33.4% vs 25.9%, p < 0.0001). None of the 105 health-care professionals working during the study time lapse exhibited anti-SARS-CoV-2 seroconversion. Among the 589 patients with information available, 54.9% declared no medical consultation at all prior to coming to ED, while only 40 (of which 27 with fever) had been examined by their GP before coming to ED. Nevertheless, 35.6% of the cases were already taking medications. None of the 9 patients requiring intensive care reported recent pediatric consultation, despite symptoms duration up to 30 days.
CONCLUSION: Our results provide evidence that the reduced capacity of primary care facilities during the national lockdown may have caused a high rate of self-medication as well as a delayed provision of care in some patients. Identification of pediatric patients affected with SARS-CoV-2 infection remains a challenge because of the absence of reliable predictive factors. Finally, the use of specific triage centers, with dedicated pathways to diagnose SARS-CoV-2 infection, trace contacts and allow adequate care after swabs, is effective in preventing spreading of the infection.

Entities:  

Keywords:  COVID-19; Emergency care; Infection control strategy; Triage

Year:  2021        PMID: 33514406     DOI: 10.1186/s13052-021-00963-3

Source DB:  PubMed          Journal:  Ital J Pediatr        ISSN: 1720-8424            Impact factor:   2.638


  2 in total

1.  Effect of Population Lockdown on Pediatric Emergency Room Demands in the Era of COVID-19.

Authors:  Francesco Valitutti; Letizia Zenzeri; Angela Mauro; Rosario Pacifico; Micaela Borrelli; Stefania Muzzica; Giovanni Boccia; Vincenzo Tipo; Pietro Vajro
Journal:  Front Pediatr       Date:  2020-09-18       Impact factor: 3.418

2.  Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units.

Authors:  Lara S Shekerdemian; Nabihah R Mahmood; Katie K Wolfe; Becky J Riggs; Catherine E Ross; Christine A McKiernan; Sabrina M Heidemann; Lawrence C Kleinman; Anita I Sen; Mark W Hall; Margaret A Priestley; John K McGuire; Konstantinos Boukas; Matthew P Sharron; Jeffrey P Burns
Journal:  JAMA Pediatr       Date:  2020-09-01       Impact factor: 16.193

  2 in total
  1 in total

1.  Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antigen detection in the Emergency Department: data from a pediatric cohort during the fourth COVID-19 wave in Italy.

Authors:  Angela Pepe; Francesco Valitutti; Deborah Veneruso; Martina Bove; Anna Giulia Elena De Anseris; Lucia Nazzaro; Pasquale Pisano; Daniela Melis; Claudia Mandato
Journal:  Ital J Pediatr       Date:  2022-08-26       Impact factor: 3.288

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.